CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Growth in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 2,070,000 shares, an increase of 202.9% from the November 15th total of 683,300 shares. Based on an average trading volume of 15,090,000 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group raised CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Tuesday, September 10th.

CNS Pharmaceuticals Price Performance

CNSP traded down $0.01 during trading on Friday, reaching $0.10. 1,679,422 shares of the stock traded hands, compared to its average volume of 5,556,652. CNS Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $100.50. The stock’s 50-day simple moving average is $0.12 and its two-hundred day simple moving average is $1.10. The stock has a market cap of $5.73 million, a price-to-earnings ratio of 0.00 and a beta of 2.55.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.